Serum Levels of Albumin–β-Amyloid Complex in Patients with Depression

Inoue, Megumi; Baba, Hajime; Yamamoto, Keiichi; Shimada, Hiroyuki; Yamakawa, Yoshihiro; Suzuki, Tomohiko; Miki, Takami; Arai, Heii

doi:10.1016/j.jagp.2016.05.005

Cited by 7 publications

(4 citation statements)

References 56 publications

(73 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is for the first time in our knowledge that four different brain areas are analysed obtaining transcriptomic dysregulation, which captures dynamic changes in the gene regulation before the onset of AD in a mouse model. In fact, this model provides App, Prnp, Ciart and Dbp as possible shared biomarkers of AD and MD in all four brain analysed regions, despite the implications of App and Prnp in MD remaining unclear [70,108,109]. However, there are some dysregulated genes in a region-specific manner that could also be referred as biomarker, including Cdh23, Ptx4 and Mc4r genes in the hippocampus and the clock genes Nr1d1 and Bhlhe41, Maml3, Zap70, Itgax and App in PFC of transgenic mice.…”

Section: Discussionmentioning

confidence: 96%

Comorbidity between Alzheimer’s disease and major depression: a behavioural and transcriptomic characterization study in mice

et al. 2021

View full text Add to dashboard Cite

Background Major depression (MD) is the most prevalent psychiatric disease in the population and is considered a prodromal stage of the Alzheimer’s disease (AD). Despite both diseases having a robust genetic component, the common transcriptomic signature remains unknown. Methods We investigated the cognitive and emotional behavioural responses in 3- and 6-month-old APP/PSEN1-Tg mice, before β-amyloid plaques were detected. We studied the genetic and pathway deregulation in the prefrontal cortex, striatum, hippocampus and amygdala of mice at both ages, using transcriptomic and functional data analysis. Results We found that depressive-like and anxiety-like behaviours, as well as memory impairments, are already present at 3-month-old APP/PSEN1-Tg mutant mice together with the deregulation of several genes, such as Ciart, Grin3b, Nr1d1 and Mc4r, and other genes including components of the circadian rhythms, electron transport chain and neurotransmission in all brain areas. Extending these results to human data performing GSEA analysis using DisGeNET database, it provides translational support for common deregulated gene sets related to MD and AD. Conclusions The present study sheds light on the shared genetic bases between MD and AD, based on a comprehensive characterization from the behavioural to transcriptomic level. These findings suggest that late MD could be an early manifestation of AD.

show abstract

Section: Discussionmentioning

confidence: 96%

Comorbidity between Alzheimer’s disease and major depression: a behavioural and transcriptomic characterization study in mice

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The APP/PSEN1-Tg model of AD could recreate the early-depressive symptoms before developing AD, as a prodromal stage of the neurodegenerative disease. In fact, this model provides App, Prnp, Ciart and Dbp as possible shared biomarkers of AD and MD, despite the implications of App and Prnp in MD remaining unclear [54][55][56] . In this sense, further studies combining post-mortem human tissues of PFC, striatum, hippocampus and amygdala from AD patients with and without an early history of depression, and transcriptomic analysis could help to provide additional evidence on the combined biological signature of both diseases.…”

Section: Discussionmentioning

confidence: 99%

Behavioural and transcriptomic characterization of the comorbidity between Alzheimer’s disease and Major Depression

Martín‐Sánchez

Piñero

Nonell

et al. 2020

Preprint

View full text Add to dashboard Cite

Major Depression (MD) is the most prevalent psychiatric disease in the population and is considered a prodromal stage of the Alzheimer s disease (AD). Despite both diseases having a robust genetic component, the common transcriptomic signature remains unknown. In this regard, we investigated the cognitive and emotional responses in 3- and 6-month-old in APP/PSEN1-Tg mutant mice, before beta-amyloid plaques were detected. Then, we studied the deregulation of genes and pathways in prefrontal cortex, striatum, hippocampus and amygdala, using transcriptomic and functional data analysis. The results demonstrated that depressive-like and anxiety-like behaviours, as well as memory impairments are already present at 3-month-old together with the deregulation of several genes and gene sets, including components of the circadian rhythms, electronic transport chain and neurotransmission. Finally, DisGeNET GSEA provides translational support for common depregulated gene sets related to MD and AD. Altogether, the results demonstrate that MD could be an early manifestation of AD.

show abstract

“…EVs increase the permeability of the BBB Leakage of the BBB, which is related to abnormalities in glutamatergic transmission and neuroinflammation, [57] has been observed in neurodegenerative diseases and some types of mental disorders. [24,[58][59][60] Proteomic studies also revealed that several neurodegenerative diseases biomarkers such as amyloid precursor protein and prion protein were enriched in neuron-derived or glia-derived EVs in human cerebrospinal fluid (CSF), [61] aligning with cognitive decline in several mental disorders including schizophrenia, [62] later-life MDD, [63] autism spectrum disorder (ASD), [64] sleep disorder (SD), [65] and PTSD. [65]Therefore, EVs might be involved in the dissemination of the pathological changes from brain to other tissues.…”

Section: The Neuropathological Underpinningsmentioning

confidence: 99%

Extracellular Vesicles in Mental Disorders: A State-of-art Review

Kong¹,

Hu²,

Lai³

et al. 2023

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Extracellular vesicles (EVs) are nanoscale particles with various physiological functions including mediating cellular communication in the central nervous system (CNS), which indicates a linkage between these particles and mental disorders such as schizophrenia, bipolar disorder, major depressive disorder, etc. To date, known characteristics of mental disorders are mainly neuroinflammation and dysfunctions of homeostasis in the CNS, and EVs are proven to be able to regulate these pathological processes. In addition, studies have found that some cargo of EVs, especially miRNAs, were significantly up-or down-regulated in patients with mental disorders. For many years, interest has been generated in exploring new diagnostic and therapeutic methods for mental disorders, but scale assessment and routine drug intervention are still the first-line applications so far. Therefore, underlying the downstream functions of EVs and their cargo may help uncover the pathogenetic mechanisms of mental disorders as well as provide novel biomarkers and therapeutic candidates. This review aims to address the connection between EVs and mental disorders, and discuss the current strategies that focus on EVs-related psychiatric detection and therapy.

show abstract

Serum Levels of Albumin–β-Amyloid Complex in Patients with Depression

Cited by 7 publications

References 56 publications

Comorbidity between Alzheimer’s disease and major depression: a behavioural and transcriptomic characterization study in mice

Comorbidity between Alzheimer’s disease and major depression: a behavioural and transcriptomic characterization study in mice

Behavioural and transcriptomic characterization of the comorbidity between Alzheimer’s disease and Major Depression

Extracellular Vesicles in Mental Disorders: A State-of-art Review

Contact Info

Product

Resources

About